Recurrent non-melanoma skin cancer: Remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3871-3875

  Signorell, J ^a   Hunziker, T ^b   Martinelli, M ^a   Koestner, S C ^a   Mohacsi, P J ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORHEXIDINE; CYCLOSPORIN; FLUOROURACIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SIMVASTATIN; TACROLIMUS;

ACTINIC KERATOSIS; ADULT; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CARCINOGENESIS; CASE REPORT; CORONARY ARTERY DISEASE; CRYOTHERAPY; DRUG INDUCED CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EAR; FACE; GRAFT RECIPIENT; GRAFT REJECTION; HEAD AND NECK CARCINOMA; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIP CARCINOMA; LOWER LIP; NOCARDIOSIS; NOSE CARCINOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SCALP; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SUNBURN;

CALCINEURIN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN NEOPLASMS; TACROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78649452424     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.090     Document Type: Article

References (57)

1. S. Euvrard, J. Kanitakis, and A. Claudy Skin cancers after organ transplantation N Engl J Med 348 2003 1681
2. D. Berg, and C.C. Otley Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management J Am Acad Dermatol 47 2002 1 quiz 1820
3. J.N. Bavinck, A. De Boer, and B.J. Vermeer Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients Br J Dermatol 129 1993 242
4. J.N. Bouwes Bavinck, D.R. Hardie, and A. Green The risk of skin cancer in renal transplant recipients in Queensland, Australia A follow-up study Transplantation 61 1996 715
5. M.C. Webb, F. Compton, and P.A. Andrews Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre Transplant Proc 29 1997 828
6. N. Arichi, H. Kishikawa, and K. Nishimura Malignancy following kidney transplantation Transplant Proc 40 2008 2400
7. S. Caillard, V. Dharnidharka, and L. Agodoa Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression Transplantation 80 2005 1233
8. I. Cowlrick, H. Delventhal, and K. Kaipainen Three-year follow-up of malignancies in tacrolimus-treated renal recipientsan analysis of European multicentre studies Clin Transplant 22 2008 372
9. J. Dantal, M. Hourmant, and D. Cantarovich Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Lancet 351 1998 623
10. B.L. Kasiske, J.J. Snyder, and D.T. Gilbertson Cancer after kidney transplantation in the United States Am J Transplant 4 2004 905
11. R. Marcen, J. Pascual, and A.M. Tato Influence of immunosuppression on the prevalence of cancer after kidney transplantation Transplant Proc 35 2003 1714
12. M.D. Navarro, M. Lopez-Andreu, and A. Rodriguez-Benot Cancer incidence and survival in kidney transplant patients Transplant Proc 40 2008 2936
13. R. Morris Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides Transplant Rev 6 1992 39
14. Epailly E, Albanell J, Andreassen A,, et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. submitted 2010
15. A.R. Raimondi, A. Molinolo, and J.S. Gutkind Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model Cancer Res 69 2009 4159
16. A.L. Rival-Tringali, S. Euvrard, and E. Decullier Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas Anticancer Res 29 2009 1927
17. C. Hiesse, P. Rieu, and F. Kriaa Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period Transplant Proc 29 1997 831
18. P. Jensen, S. Hansen, and B. Moller Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens J Am Acad Dermatol 40 2 Pt 1 1999 177
19. E.Q. Sanchez, S. Marubashi, and G. Jung De novo tumors after liver transplantation: a single-institution experience Liver Transpl 8 2002 285
20. J.T. Winkelhorst, W.J. Brokelman, and R.G. Tiggeler Incidence and clinical course of de-novo malignancies in renal allograft recipients Eur J Surg Oncol 27 2001 409
21. D.E. Brash Molecular biology of skin cancer. Cancer: Principles & Practice of Oncology 1997 Lippincott-Raven Philadelphia 1879
22. D. Grossman, and D.J. Leffell The molecular basis of nonmelanoma skin cancer: new understanding Arch Dermatol 133 1997 1263
23. A. Espana, M.A. Martinez-Gonzalez, and M. Garcia-Granero A prospective study of incident nonmelanoma skin cancer in heart transplant recipients J Invest Dermatol 115 2000 1158
24. A. Geusau, D. Dunkler, and E. Messeritsch Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy Int J Dermatol 47 2008 918
25. J. McLelland, A. Rees, and G. Williams The incidence of immunosuppression-related skin disease in long-term transplant patients Transplantation 46 1988 871
26. L.S. Roeger, A.G.R. Sheil, and A.P.S. Disney Risk factors associated with the development of squamous cell carcinoma in immunosuppressed renal transplant recipients Clin Transplantation 6 1997 202
27. I. Blohme, and O. Larko Premalignant and malignant skin lesions in renal transplant patients Transplantation 37 1984 165
28. J. Boyle, R.M. MacKie, and J.D. Briggs Cancer, warts, and sunshine in renal transplant patients A case-control study Lancet 1 1984 702
29. A.K. Gupta, C.J. Cardella, and H.F. Haberman Cutaneous malignant neoplasms in patients with renal transplants Arch Dermatol 122 1986 1288
30. M.M. Hartevelt, J.N. Bavinck, and A.M. Kootte Incidence of skin cancer after renal transplantation in The Netherlands Transplantation 49 1990 506
31. R. Adamson, E. Obispo, and S. Dychter High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study Transplant Proc 30 1998 1124
32. S. Euvrard, J. Kanitakis, and C. Pouteil-Noble Aggressive squamous cell carcinomas in organ transplant recipients Transplant Proc 27 1995 1767
33. M. Guba, P. von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
34. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530
35. G.E. Koehl, J. Andrassy, and M. Guba Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice Transplantation 77 2004 1319
36. A.L. Caforio, A.B. Fortina, and S. Piaserico Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy Circulation 102 19 suppl 3 2000 III222
37. A.B. Fortina, S. Piaserico, and A.L. Caforio Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients Arch Dermatol 140 2004 1079
38. P. O'Donovan, C.M. Perrett, and X. Zhang Azathioprine and UVA light generate mutagenic oxidative DNA damage Science 309 2005 1871
39. A. Gutierrez-Dalmau, and J.M. Campistol Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review Drugs 67 2007 1167
40. F.J. Duncan, B.C. Wulff, and K.L. Tober Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis Am J Transplant 7 2007 2693
41. H. Lehmkuhl, H. Ross, and H. Eisen Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure Transplant Proc 37 2005 4145
42. R. Oberbauer, G. Segoloni, and J.M. Campistol Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 month after transplantation Transpl Int 18 2005 22
43. M. Schweiger, A. Walser, and G. Brenner Everolimus and reduced cyclosporin through levels in maintenance heart transplantation recipients Transpl Immunol 16 2006 46
44. S. Vitko, H. Tedesco, and J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626
45. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
46. Y.K. Yakupoglu, J.F. Buell, and S. Woodle Individualization of immunosuppressive therapy III. Sirolimus associated with a reduced incidence of malignancy Transplant Proc 38 2006 358
47. J.M. Campistol, J. Eris, and R. Oberbauer Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581
48. G. Stallone, A. Schena, and B. Infante Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317
49. S.C. Zmonarski, M. Boratynska, and J. Rabczynski Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment Transplant Proc 37 2005 964
50. A. Zuckermann, N. Manito, and E. Epailly Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation J Heart Lung Transplant 27 2008 141
51. A. Fernandez, R. Marcen, and J. Pascual Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia Transplant Proc 38 2006 2453
52. J. Pascual, A.M. Fernandez, and R. Marcen Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasiaa case report Nephrol Dial Transplant 21 suppl 3 2006 iii38
53. J.W. de Fijter Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation Nephrol Dial Transplant 22 suppl 1 2007 i23
54. M.G. Crespo-Leiro, L. Alonso-Pulpon, and J.A. Vazquez de Prada Malignancy after heart transplantation: incidence, prognosis and risk factors Am J Transplant 8 2008 1031
55. J.O. O'Neill, L.B. Edwards, and D.O. Taylor Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 1186
56. K. Wang, H. Zhang, and Y. Li Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review Transplant Proc 36 2004 2068
57. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449